Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as...
Triple the Probiotics, Triple the Relief: Life-Space Launches Triple Strength Probiotics in Southeast Asia
Engineered by Australia's leading probiotics expert, this high CFU probiotic delivers the ultimate gut defense, helping to reduce gut transit time by up to 18 hours. SINGAPORE, Nov. 24, 2025 /PRNewswire/ -- Life-Space, Australia's No.1 probiotic brand, proudly unveils Triple Strength Probiotics, a flash charged probiotic designed to deliver intensive gut health support for those with more demanding digestive needs. With 15...
HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Cleared AI “SOMNUM”
Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency FDA-cleared AI solution shortens clinical trial timelines while ensuring data reliability Expanded global partnerships with CROs enable a large-scale clinical data analysis platform BOSTON, Nov. 24, 2025 /PRNewswire/ -- HoneyNaps, an AI-driven sleep-medicine technology company, announced...
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a favourable safety profile, and real-world public health impact. Administration can be timed during the first year of life to provide protection from birth,...
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader PIN-5018 in a Phase 1 clinical trial. The first patient enrolled has adenoid cystic...
Chula Veterinarians Perform Thailand’s First Pacemaker Implant in a Cat
BANGKOK, Nov. 24, 2025 /PRNewswire/ -- In a groundbreaking medical milestone, veterinarians from Chulalongkorn University's Faculty of Veterinary Science have successfully performed Thailand's first pacemaker implantation in a cat, marking a new era in advanced veterinary cardiology. The procedure, led by Assoc. Prof. Dr. Anusak Kijtawornrat from the Department of Physiology, demonstrates Thailand's growing capacity in high-precision animal healthcare. ...
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March...
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, announced today...
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition in Europe and the eighth consecutive Global Industry Forum organized by GenScript since its debut at the 2020 J.P. Morgan Healthcare...
Global Health Leaders Convene in Kuala Lumpur from 25-27 November for Malaysia International Healthcare Megatrends 2025
A Major Conference on Innovation, Digital Health and Sustainable Care Systems KUALA LUMPUR, Malaysia, Nov. 22, 2025 /PRNewswire/ -- Healthcare leaders, policymakers and innovators from around the world will convene in Malaysia next week for the Malaysia International Healthcare (MIH) Megatrends 2025, a three-day global conference dedicated to reimagining the future of health systems. ...
